Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180101 | 0.83 | GPBAR1 (0.73) | KMT2AGPBAR1TSHRMCOLN3MAPT | |
| SCHEMBL12655867 | 0.81 | GPBAR1 (0.50) | KMT2AGPBAR1TSHRMCOLN3PKM | |
| SCHEMBL9976104 | 0.81 | LMNA (0.58) | KMT2AGPBAR1TSHRMCOLN3MAPT | |
| SCHEMBL4184459 | 0.79 | GPBAR1 (0.74) | KMT2AGPBAR1TSHRMCOLN3MAPT | |
| SCHEMBL27334375 | 0.77 | KMT2A (0.58) | KMT2AGPBAR1TSHRMCOLN3MAPT | |
| SCHEMBL12655869 | 0.76 | CYP1A2 (0.42) | KMT2AGPBAR1TSHRMCOLN3PKM | |
| SCHEMBL1352340 | 0.74 | PKM (0.77) | KMT2AIKBKBCHUKTSHRMAPT | |
| Hydrochloric Acid SCHEMBL3245890 | 0.73 | PKM (0.75) | KMT2AIKBKBCHUKTSHRMAPT | |
| SCHEMBL10573633 | 0.73 | KMT2A (0.64) | KMT2ATSHRMCOLN3MAPTALDH1A1 | |
| SCHEMBL30885724 | 0.73 | PKM (0.61) | KMT2ATSHRMAPTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5559109-A | Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist | SANKKO COMPANY, LIMITED (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5556852-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0395446-B1 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | SANKYO CO (JP) | 1995-03-01 | — | — | EP | disclosed |
| US-5369106-A | N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists | SANKYO COMPANY, LIMITED (JP) | 1994-11-29 | — | — | US | disclosed |
| US-5192766-A | Platelet activating factor antagonist | SANKYO COMPANY, LIMITED (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0395446-A2 | N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists | Sankyo Company Limited (JP) | 1990-10-31 | — | — | EP | disclosed |